{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:49:08Z","timestamp":1770497348844,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T00:00:00Z","timestamp":1441152000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline (GB)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40261-015-0322-6","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T11:13:16Z","timestamp":1441105996000},"page":"685-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses"],"prefix":"10.1007","volume":"35","author":[{"given":"Ahmar","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil C.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,2]]},"reference":[{"key":"322_CR1","first-page":"39","volume":"1","author":"S Saha","year":"2006","unstructured":"Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:39\u201347.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"322_CR2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","volume":"184","author":"M Bafadhel","year":"2011","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662\u201371.","journal-title":"Am J Respir Crit Care Med."},{"issue":"Suppl. 58","key":"322_CR3","first-page":"4416","volume":"44","author":"D Price","year":"2014","unstructured":"Price D, Rigazio A, Postma D, Papi A, Guy B, Agusti A, et al. Blood eosinophilia and the number of exacerbations in COPD patients [abstract]. Eur Respir J. 2014;44(Suppl. 58):4416.","journal-title":"Eur Respir J."},{"key":"322_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","volume":"186","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48\u201355.","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"322_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","volume":"3","author":"S Pascoe","year":"2015","unstructured":"Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435\u201342.","journal-title":"Lancet Respir Med."},{"key":"322_CR6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1378\/chest.13-1579","volume":"145","author":"B Celli","year":"2014","unstructured":"Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg C, et al. Once-daily umeclidinium\/vilanterol 125\/25\u00a0mcg in COPD: a randomized, controlled study. Chest. 2014;145:981\u201391.","journal-title":"Chest."},{"key":"322_CR7","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25\u00a0mcg in COPD. Respir Med. 2013;107:1538\u201346.","journal-title":"Respir Med."},{"key":"322_CR8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472\u201386.","journal-title":"Lancet Respir Med."},{"issue":"4","key":"322_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","volume":"192","author":"SH Siddiqui","year":"2015","unstructured":"Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523\u20135.","journal-title":"Am J Respir Crit Care Med."},{"key":"322_CR10","first-page":"587","volume":"7","author":"R Jen","year":"2012","unstructured":"Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J COPD. 2012;7:587\u201395.","journal-title":"Int J COPD."},{"key":"322_CR11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450\u2013504.","journal-title":"Pharmacol Rev."},{"key":"322_CR12","doi-asserted-by":"crossref","first-page":"409580","DOI":"10.1155\/2012\/409580","volume":"2012","author":"G Karakiulakis","year":"2012","unstructured":"Karakiulakis G, Roth M. Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects. Mediat Inflamm. 2012;2012:409580.","journal-title":"Mediat Inflamm."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0322-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0322-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0322-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:19Z","timestamp":1551186739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0322-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,2]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0322-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,2]]}}}